1. Zittermann A. Vitamin D and disease prevention with special reference to cardiovascular disease. Prog Biophys Mol Biol 2006; 92(1): 39-48.

2. Holick M.F. Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006; 116: 2062-2072.

3. Napiórkowska L., Franek E. Rola oznaczania witaminy D w praktyce. Choroby Serca i Naczyń 2009; 6(4): 203-210.

4. Kmieć P., Żmijewski M., Lizakowska-Kmieć M., Sworczak K. Vitamin D deficiency among adults from Northern Poland (54°N) after months of low and high natural UVB radiation. Endokrynol Pol 2015; 66(1): 30-38.

5. Kmieć P., Żmijewski M., Waszak P., Sworczak K i wsp. Vitamin D deficiency during winter months among an adult, predominantly urban, population in Northern Poland. Endokrynol Pol 2014; 65(2): 105-113.

6. Holick M.F. Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006; 116: 2062-2072.

7. Stumpf W.E., Sar M., Reid F.A., Tanaka Y. i wsp. Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science 1979; 206: 1188-1190.

8. Grygiel-Górniak B., Puszczewicz M. Witamina D – nowe spojrzenie w medycynie i reumatologii. Postepy Hig Med Dosw 2014; 68: 359-368.

9. Losel R.M., Falkenstein E., Feuring M., Schultz A. i wsp. Nongenomic steroid action: controversies, questions, and answers. Physiol Rev 2003; 83: 965-1016.

10. Norman A.W. Minireview: vitamin D receptor: new assignments for and already busy receptor. Endocrinology 2006; 147: 5542-5548.

11. DeLuca H.F. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004; 80: 1689S-1696S.

12. Baeke F., Takiishi T., Kort H. i wsp. Vitamin D; modulator of the immune system. Curr Opin Pharmacol 2010; 10: 482- 496.

13. Nijnik A., Hancok R.E. The roles of cathelicidin LL-37 in immune defences and novel clinical applications. Curr Opin Hematol 2009; 16: 41-47.

14. Chun R.F., Adanis J.S., Hewison M. Back to the future: a new look at „old” vitamin D. J Endocrinol 2008; 198: 261-269.

15. Jeng L., Yamshchikov A.V., Judd S.E. i wsp. Alterations in vitamin D status and anti-microbial peptide levels in patients in the intensive care unit with sepsis. J Transl Med 2009; 7: 28. doi: 10.1186/1479-5876-7-28.

16. Urashima M., Segawa T., Okazaki M. i wsp. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. Am J Clin Nutr 2010; 91(5):1255-60. doi: 10.3945/ajcn.2009.29094.

17. Youssef D. A., Miller C.W., El-Abbassi A.M. i wsp. Antimicrobial implications of vitamina D. Dermatoendocrinol 2011; 3: 200-229.

18. Cannell J.J., Vieth R., Umhan J.C. i wsp. Epidemic influenza and vitamin D. Epidemiol Infect 2006; 134: 1129-1140.

19. Ginde A.A., Mansbach J.M., Camargo C.A Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 2009; 169(4): 384-390.

20. Liu P.T., Stenger S., Li H. i wsp. Toll-like receptor triggering of a vitamin D mediated human antimicrobial responce. Science 2006; 311: 1770-1773.

21. Adams J.S., Ren S., Lin P.T. Vitamin D directed rheostatic regulation of mocyte antimicrobial responses. J Immunol 2009; 182: 4289-4295.

22. Kuźmińska M. Witamina D a układ oddechowy. Post N Med. 2012; 3: 241-246.

23. Ginde A.A., Mansbach J.M., Camargo C.A. Jr. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Arch Intern Med 2009; 169(4): 384-390.

24. Brehm J.M., Schuemann B., Fuhlbrigge A.L., Hollis B.W. i wsp. Serum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study. J Allergy Clin Immunol 2010; 126(1): 52-58.

25. Sajkowska J., Paradowska K. Wielokierunkowe działanie witaminy D. Biul Wydz Farm WUM 2014; 1: 1-6.

26. Gedik O., Akalin S. Effects of vitamin D deficiency and repletion on insulin and glucagon secretion in man. Diabetologia 1986; 29:142-145.

27. Inomata S., Kadowaski S., Yamatani T. i wsp. Effect of 1(OH)-vitamin D3 on insulin secretion in diabetes mellitus. Bone Miner 1986; 1: 187-192.

28. Draznin B., Sussman K., Kao M. i wsp. The existence of an optimal range of cytosolic free calcium for insulin-stimulated glucose transport in rat adipocites. J Biol Chem 1987; 262: 14385-14388.

29. Pittas A. G. Dawson-Hughes B., Li T. i wsp. Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 2006;29: 650-656.

30. Pittas A. G. Harris S.S., Stark P.C. i wsp. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in non-diabetic adults. Diabetes Care 2007; 30: 980-986.

31. Żukowska-Szczechowska E., Kiszka B. Niedobór witaminy D – rozpoznawanie i postępowanie w celu redukcji ryzyka sercowo- naczyniowego u chorych na cukrzycę. Forum Zaburzeń Metabolicznych 2011; 2(2): 151-157.

32. Szewczyk L., Piekarski R. Rola witaminy D3 w cukrzycy typu 1. Endokrynol Ped 2008; 1(22): 65-70.

33. Liss Y., Frishman W.H. Vitamin D: a cardioprotective agaent? Cardiol Rev 2012; 20(1): 38-44.

34. Parker J., Hashmi O., Dutton D., Mavrodaris A. Levels of vitamin D and cardiometabolic disorder: systemic review and meta-analysis. Maturitas 2010; 65(3): 225-236.

35. Holick M.F. The vitamin D deficiency pandemic and consequences for nonskeletal health: mechanisms of action. Mol Aspects Med 2008; 29(6): 361-368.

36. Etgen T., Bickel H., Förstl H. Metabolic and endocrine factors in mild cognitive impairment. Ageing Res Rev 2010; 9: 280-288.

37. Jasik A., Tałałaj M. Witamina D a reumatoidalne zapalenie stawów. Post N Med. 2012; 3: 237-240.

38. Tetlow L. C., Woolley D.E. The effect of ,25-dihydrovitamin D3 on matrix metalloproteinase and prostaglandin E2 production by cells of the rhumatoid lesion. Arthritis Res 1999; 1: 63-70.

39. Rossini M., Maddali Bongi S., La Montagna G., Minisola G. i wsp. Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability. Arthritis Res Ther 2010; 12: R216-R223.

40. Merlino L.A., Curtis J., Mikuls T.R., i wsp. Vitamin D intake is inversely associated with rheumtoid arthritis: results from the Iowa Women’s Health Study. Arthritis Rheum 2004; 50: 72-77.

41. Holick M.F. Clinical efficacy of 1,25-dihydroxyvitamin D3 and its analogues in the treatment of psoriasis. Retinoids 1998; 14: 12-17.

42. Carboni I., de Falice C., Bergamin A. i wsp. Topical use of calcitriol 3μg/g ointment in the treatment of mild-to-moderate psoriasis: results from an open-label study. JEADV 2005; 19(suppl 3): 11-13.

43. van de Kerkof P.C., Berker J., Griffiths C.E. i wsp. Psoriasis: consensus on topical therapies. JEADV 2008; 22: 859-870.

44. Yüksel RN., Altunsoy N., Tikir B. i wsp. Correlation between total vitamin D levels and psychotic psychopathology in patients with schizophrenia: therapeutic implications for add-on vitamin D augmentation. Ther Adv Psychopharmacol 2014; 4(6): 268-275.

45. Gowda U., Mutowo MP., Smith BJ. i wsp. Vitamin D supplementation to reduce depression in adults: meta-analysis of randomized controlled trials. Nutrition 2015; 31(3): 421-429.

46. Józefowicz O., Rabe-Jabłońska J., Woźniacka A. i wsp. Analysis of vitamin D status in major depression. J Psychiatr Pract 2014; 20(5): 329-337.

47. Grant W.B. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002; 94: 1867-1875.

48. Raimondi S., Johansson H. Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. Carcinogenesis 2009; 30: 1170-1180.

49. Gandini S., Boniol m, Metaanalysis of observational studies of serum 25-hydroksyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. Int J Cancer 2011; 128(6): 1414-1424.

50. Bouillon R., Eelen G. Vitamin D and cancer. J Steroid Biochem Biol 2006; 102: 156-162.

51. Garland C.F., Gorham E.D., Mohr S.B., Garland F.C. Vitamin D for cancer prevention: global perspective. Ann Epidemiol 2009; 19(7): 468-483.

52. Kuryłowicz A., Bednarczuk T., Neuman J., The influence of vitamin D deficiency on cancers and autoimmune diseases development. Endokrynol Pol 2007; 58(2): 140-152.

53. Lips P. Relative value of 25(OH)D and 1,25(OH)D mesurements. J Bone Miner Res 2007; 22: 1668-71.

54. Płudowski P., Karczmarewicz E., Chlebna-Sokół D., Czech- Kowalska J. i wsp. Witamina D: Rekomendacje dawkowania w populacji osób zdrowych oraz w grupach ryzyka deficytów – wytyczne dla Europy Środkowej 2013 r. Standardy Medyczne. Pediatria 2013; 10:573-578.

55. Bischoff-Ferrari H.A., Willet W.C., Wong J.B. i wsp. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 2005; 293: 2257- 2264.

56. Kuthan R. Niedobór wapnia, witaminy D i jej metabolitów w osteoporozie. Lek w Polsce 2014; 24(6): 34-44.

57. Brunel E, Schnitzler M, Foidart-Dessalle M. i wsp. A doubleblind, placebo controlled, randomized trial to assess the impact of a monthly administration of 50,000 IU of vitamin D3 for 6 months on serum levels of 25-hydroxyvitamin D in healthy young adults. Int J Endocrinol 2013; 2013:652648. doi: 10.1155/2013/652648.